Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Acquisitions (2017)

Viridian Therapeutics, Inc.\DE has reported Acquisitions over the past 1 years, most recently at $1.3 million for Q1 2017.

  • Quarterly results put Acquisitions at $1.3 million for Q1 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $1.3 million (changed N/A YoY), and the annual figure for FY2020 was $29.4 million, changed.
  • Acquisitions for Q1 2017 was $1.3 million at Viridian Therapeutics, Inc.\DE.
  • Over the last five years, Acquisitions for VRDN hit a ceiling of $1.3 million in Q1 2017 and a floor of $1.3 million in Q1 2017.